← Leaderboards
Douglas W Losordo
Lisata Therapeutics Inc
$1,941,300
Attributed
$1,941,300
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $973.5K · FY2017–19$1M$750K$500K$250K$0
'17
'18
'19
Funding mix
By agency
NIH$1,941,300 · 1
By mechanism
R44$1,941,300 · 1
Top collaborators
No co-investigators on record.
Most similar at Lisata Therapeutics Inc
Same institution · by research overlap
- Denis Overend Rodgerson$934,649
Others in their field
Other Emerging Leaders on “Acute Myocardial Infarction”
- Vera Hoffman · Reveal Pharma$8,460,813
- Rishi Kumar Wadhera · Beth Israel Deaconess Medical Center$5,884,036
- Jeffrey Lee Birk · Columbia University Health Sciences$4,201,040
- Kiyotake Ishikawa · Icahn School Of Medicine At Mount Sinai$4,200,163
- Magali Noval Rivas · Cedars-Sinai Medical Center$3,857,500
- Amanda A Fox · Ut Southwestern Medical Center$3,679,471
Research focus
Acute Myocardial InfarctionAdenosineAngiogenesisArterial TonometryAssociated SymptomAutologousBackBiological SciencesBlood Component RemovalBlood FlowBone CellBone MarrowCardiacCardiovascular DiseasesCardiovascular SystemCd34 GeneCellsCell TherapyCharacteristicsChestChest PainClinicClinical ResearchAcetylcholine
Grant awards (3)
Exploratory Clinical Study To Evaluate The Potential Bioactivity Of CLBS16 In Patients With Coronary Microvascular Dysfunction$214,260
R44 · FY2019 · HL · contact PI
Exploratory Clinical Study to Evaluate the Potential Bioactivity of CLBS14 in Patients with Coronary Microvascular Dysfunction$973,475
R44 · FY2018 · HL · contact PI
Exploratory Clinical Study to Evaluate the Potential Bioactivity of CLBS14 in Patients with Coronary Microvascular Dysfunction$753,565
R44 · FY2017 · HL · contact PI